Published in FEBS J on June 15, 2009
Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol (2012) 0.93
Adenoviral targeting using genetically incorporated camelid single variable domains. Lab Invest (2014) 0.83
Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation. Mol Biosyst (2010) 0.83
Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity. Cancer Biol Ther (2016) 0.80
Nanobodies as modulators of inflammation: potential applications for acute brain injury. Front Cell Neurosci (2014) 0.79
Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display. Mol Cell Proteomics (2013) 0.79
Crystal structure of a human single domain antibody dimer formed through V(H)-V(H) non-covalent interactions. PLoS One (2012) 0.78
Selection of intracellular single-domain antibodies targeting the HIV-1 Vpr protein by cytoplasmic yeast two-hybrid system. PLoS One (2014) 0.76
A novel bispecific antibody, BiSS, with potent anti-cancer activities. Cancer Biol Ther (2016) 0.75
State of the art in tumor antigen and biomarker discovery. Cancers (Basel) (2011) 0.75
Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol (2009) 3.05
A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells. Nucleic Acids Res (2003) 2.49
A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res (2006) 2.38
Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. Science (2011) 2.32
Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. J Mol Biol (2005) 2.04
Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol (2002) 1.95
Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog (2007) 1.93
Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs (2010) 1.89
FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol (2007) 1.81
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood (2010) 1.74
Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta (2008) 1.54
Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J Nucl Med (2010) 1.45
Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med (2014) 1.39
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res (2007) 1.35
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis (2010) 1.32
CD63 tetraspanin slows down cell migration and translocates to the endosomal-lysosomal-MIICs route after extracellular stimuli in human immature dendritic cells. Blood (2004) 1.30
Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res (2008) 1.30
Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells. J Biol Chem (2001) 1.27
Chemical heterogeneity in cell death: combined synchrotron IR and fluorescence microscopy studies of single apoptotic and necrotic cells. Biopolymers (2003) 1.23
Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II. J Biol Chem (2010) 1.19
Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J (2010) 1.18
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol (2008) 1.16
Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother (2010) 1.12
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Intracellular distribution of viral gene products regulates a complex mechanism of cauliflower mosaic virus acquisition by its aphid vector. Proc Natl Acad Sci U S A (2002) 1.10
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem (2011) 1.08
Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy. Cytometry A (2008) 1.04
Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol (2003) 1.04
Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A (2002) 1.03
Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel (2009) 1.03
Evidence of a bactericidal permeability increasing protein in an invertebrate, the Crassostrea gigas Cg-BPI. Proc Natl Acad Sci U S A (2007) 1.02
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol (2005) 1.01
Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res (2008) 1.00
Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells. PLoS One (2012) 0.98
HcPro, a multifunctional protein encoded by a plant RNA virus, targets the 20S proteasome and affects its enzymic activities. J Gen Virol (2005) 0.98
Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol (2005) 0.98
Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer (2005) 0.98
Generation of llama single-domain antibodies against methotrexate, a prototypical hapten. Mol Immunol (2006) 0.98
MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin Cancer Res (2005) 0.97
Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. J Med Chem (2007) 0.96
Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol (2005) 0.96
Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes. Nanomedicine (2011) 0.96
Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett (2006) 0.95
Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood (2011) 0.95
Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med (2006) 0.94
A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol (2008) 0.94
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia (2013) 0.93
Functional specific binding of testosterone to Schistosoma haematobium 28-kilodalton glutathione S-transferase. Infect Immun (2002) 0.93
Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol (2012) 0.93
Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer. Gynecol Oncol (2011) 0.92
R-Cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase. Cancer Res (2008) 0.92
CD16b associates with high-density, detergent-resistant membranes in human neutrophils. Biochem J (2006) 0.92
Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med (2009) 0.91
Translocation of a functional protein by a voltage-dependent ion channel. Proc Natl Acad Sci U S A (2002) 0.90
Expression and folding of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm. Res Microbiol (2002) 0.89
General overview of radioimmunotherapy of solid tumors. Immunotherapy (2013) 0.89
A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem Biophys Res Commun (2003) 0.89
Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel (2007) 0.88
Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity. J Neurosci (2011) 0.88
Highly sensitive single domain antibody-quantum dot conjugates for detection of HER2 biomarker in lung and breast cancer cells. ACS Nano (2014) 0.88
Localization of the discontinuous immunodominant region recognized by human anti-thyroperoxidase autoantibodies in autoimmune thyroid diseases. J Biol Chem (2002) 0.88
Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther (2013) 0.87
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One (2013) 0.87
NMR structure of rALF-Pm3, an anti-lipopolysaccharide factor from shrimp: model of the possible lipid A-binding site. Biopolymers (2009) 0.87
Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions. J Virol (2012) 0.86
A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers. J Immunol Methods (2009) 0.86
A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One (2011) 0.85
A homogeneous resonance energy transfer-based assay to monitor MutS/DNA interactions. Anal Biochem (2008) 0.85
Antibody-antigenic peptide interactions monitored by SPR and QCM-D. A model for SPR detection of IA-2 autoantibodies in human serum. Biosens Bioelectron (2007) 0.85
Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Bioconjug Chem (2011) 0.84
Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol (2013) 0.84
Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors. Bioconjug Chem (2009) 0.84
Directed mutagenesis in region 713-720 of human thyroperoxidase assigns 713KFPED717 residues as being involved in the B domain of the discontinuous immunodominant region recognized by human autoantibodies. J Biol Chem (2004) 0.84
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer. PLoS One (2012) 0.83
Changes in the dimeric state of neuronal nitric oxide synthase affect the kinetics of secretagogue-induced insulin response. Diabetes (2004) 0.83
Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation. Mol Biosyst (2010) 0.83